The REIN-2 (Ramipril Efficacy in Nephropathy-2) study examined whether intensive BP control with the addition of a dihydropyridine calcium channel antagonist (blocker) (CCB) to those already established on an angiotensin converting enzyme (ACE) inhibitor was superior to standard BP control with an ACE inhibitor alone. This evidence concerns the gene ACE and Nephropathy.